non alcoholic fatty liver disease. Other specified inflammatory liver diseases
Conditions
Interventions
Intervention 1: IN intervention group: 750 mg L- carnitine, three times a day for three months. Intervention 2: IN control group: plasebo three times a day for three months.
Treatment - Drugs
Placebo
IN intervention group: 750 mg L- carnitine, three times a day for three months
IN control group: plasebo three times a day for three months
Sponsors
Gastroentrology Recerch Center, Ahwaz Jundishapur Medical School
Eligibility
Sex/Gender
All
Age
14 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Known case of diabetic type2 ? serum level of alanin aminotranspherase and aspartat aminotranspherase more than 2time of normal? and high level of triglicirid and cholestrol level ? ultrasonograghy evidences of fatty live. Exclusion criteria: any causes of increasing liver enzymes such as viral infections? hemochromatosis ?alfa 1 anti tripsin dificiency?Wilson’s disease? autoimmune diseases? drinking (20 and 10 grams per day for men and women, respectively)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver aminotransferase. Timepoint: Before intervention and three months after initiation of the intervention. Method of measurement: Eliza. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of triglicirid and cholestril. Timepoint: Before intervention and three months after initiation of the intervention. Method of measurement: Eliza.;Fasting blood glucos test. Timepoint: Before intervention and three months after initiation of the intervention. Method of measurement: Eliza. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactChobineh Mahmod
Jundishapur University of Medical Sciences
Outcome results
None listed